Land: Irland
Språk: engelsk
Kilde: HPRA (Health Products Regulatory Authority)
FOLINIC ACID
Pharmachemie BV
V03AF06
FOLINIC ACID
25 Mg/Ml
Solution for Injection
Product subject to prescription which may not be renewed (A)
Detoxifying agents for antineoplastic treatment
Authorised
2006-12-21
PACKAGE LEAFLET: INFORMATION FOR THE USER VORINA 25 MG/ML, SOLUTION FOR INJECTION Folinic acid READ ALL OF THIS LEAFLET CAREFULLY BEFORE THIS MEDICINE IS GIVEN TO YOU BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor, pharmacist or nurse. - If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What VoriNa is and what it is used for 2. What you need to know before you are given VoriNa 3. How VoriNa is given 4. Possible side effects 5. How to store VoriNa 6. Contents of the pack and other information 1. WHAT VORINA IS AND WHAT IT IS USED FOR VoriNa is an antidote. Antidotes prevent the damage caused by other substances. VoriNa is administered as an injection or infusion by your doctor. VoriNa is used to help prevent the side effects of treatment or overdose with the medicine methotrexate, when used in high doses. VoriNa is administered a few hours after methotrexate, to allow methotrexate to have its effect first. VoriNa is also used in combination with the medicine 5-fluorouracil for the treatment of a certain form of colon cancer (metastatic colorectal carcinoma). This therapy should only be applied when supervised by a doctor with experience in the use of cancer chemotherapeutics. Finally VoriNa is also used to prevent or treat a folate deficiency, only when it is impossible to administer folic acid tablets. USE - to diminish the harmfulness and effect of certain medicines (like methotrexate) in children and adults - in combination with th read_full_document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT VoriNa 25 mg/ml, solution for injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One ml solution for injection contains disodium folinate equivalent to 25.00 mg folinic acid. One vial of 2 ml contains disodium folinate equivalent to 50 mg folinic acid One vial of 4 ml contains disodium folinate equivalent to 100 mg folinic acid One vial of 14 ml contains disodium folinate equivalent to 350 mg folinic acid One vial of 20 ml contains disodium folinate equivalent to 500 mg folinic acid One vial of 40 ml contains disodium folinate equivalent to 1000 mg folinic acid For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Solution for injection. Clear yellow solution, free of particles. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Disodium folinate is indicated: - To diminish the toxicity and counteract the action of folic acid antagonists such as methotrexate in cytotoxic therapy and overdose in adults and children. In cytotoxic therapy, this procedure is commonly known as "Folinate Rescue" - in combination with 5-fluorouracil in cytotoxic therapy. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology _FOLINIC ACID RESCUE IN METHOTREXATE THERAPY:_ Since the folinate rescue dosage regimen depends heavily on the posology and method of the intermediate- or high- dose methotrexate administration, the methotrexate protocol will dictate the dosage regimen of folinate rescue. Therefore, it is best to refer to the applied intermediate or high dose methotrexate protocol for posology and method of administration of folinate. As far as these protocols mention calcium folinate dosages, calcium-folinate can be replaced by disodium folinate (VoriNa) using the same folinate dosages. The following guidelines read_full_document